BioCentury
ARTICLE | Company News

Amylin files Symlin MAA

May 31, 2001 7:00 AM UTC

AMLN submitted an MAA for its Symlin pramlintide synthetic analog of amylin hormone to treat patients with Type I or Type II diabetes. In January, the FDA accepted for filing AMLN's NDA for Symlin. ...